David Auth

Pathway Medical Technologies, Inc. develops, manufactures, and markets medical devices intended for the treatment of arterial disease, specifically the peripheral arterial disease. Pathway Medical Technologies was founded in 1998, and is headquartered in Kirkland, WA.

Medlogics Device Corp. was engages in the research, development and manufacture of drug eluting coating, stent and catheter solutions. The company was founded in August 2002 and headquartered in Santa Rosa, CA.

Percutaneous Systems, Inc. designs, develops, and commercializes medical devices. Its PercSys Accordion Stone Management Device and the Accordion CoAx Stone Control Devices are designed to simplify and shorten endoscopic lithotripsy procedures by combining the utility of multiple endoscopic stone management tools into a single device. The company was founded by Robert Behl in 2003 and is headquartered in Palo Alto, CA.

Ancora Heart, Inc. manufactures medical devices for the treatment of mitral valve regurgitation. It develops percutaneous cardiac procedures for mitral valve regurgitation. The company was founded in 2001 by Lewis C. Pell, Niel F. Starksen and Nathan B. Pliam and is headquartered in Santa Clara, CA.

CoAptus Medical Corporation is an early stage medical device company developing a therapeutic product for the treatment of a structural heart defect called a patent foramen ovale, or PFO. A PFO is a flap-like opening, or tunnel between the upper chambers of the heart. Normally, this passageway closes shortly after birth. However, in approximately 25% of the population, the passageway remains open or patent, and may permit the passage of blood clots or chemicals that would normally be filtered by the lungs to pass into the left heart and into the arterial circulation of the body including the brain. PFO's have been associated with stroke, transient ischemic attacks (TIA's), and migraine headaches. CoAptus is developing a non-implant, therapeutic catheter device to coapt the tunnel tissues closed and apply RF energy for a permanent seal. Nothing is left behind in the heart after the procedure is completed.

Arstasis, Inc. develops and manufactures medical devices for femoral catheterizations. It offers AXERA access device, a vascular access device that is used in patients undergoing diagnostic femoral artery catheterization procedures using 5F or 6F introducer sheaths. The company was founded in August 2004 by D. Bruce Modesitt and is headquartered in Fremont, CA.